
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5350463/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Preoperative neutrophil-to-platelet ratio as a potential prognostic factor for gastric cancer with positive peritoneal lavage cytology in the absence of other non-curative factors: a multi-institutional dataset analysis. Surgery Today, 2023, 53, 198-206.	0.7	2
2	A comparison of the effects of anti-reflux procedures during esophagogastrostomy after proximal gastrectomy on the postoperative quality of life. Surgery Today, 2023, 53, 182-191.	0.7	2
3	Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07. Gastric Cancer, 2022, 25, 188-196.	2.7	33
4	Survival analysis of a prospective multicenter observational study on surgical palliation among patients with malignant bowel obstruction caused by peritoneal dissemination of gastric cancer. Gastric Cancer, 2022, 25, 422-429.	2.7	5
5	E-PASS scoring system serves as a predictor of short- and long-term outcomes in gastric cancer surgery. Surgery Today, 2022, 52, 914-922.	0.7	2
6	International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO Câ€1). Annals of Gastroenterological Surgery, 2022, 6, 227-240.	1.2	39
7	Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1620-e1630.	1.8	15
8	SLC7A9 as a Potential Biomarker for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2022, 29, 2699-2709.	0.7	3
9	Drain Amylase Concentrations at 3 h After Gastrectomy Enhance Early Prediction of Postoperative Peripancreatic Inflammatory Fluid Collection. World Journal of Surgery, 2022, 46, 648-655.	0.8	Ο
10	Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: A phase II study. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 578-585.	0.7	6
11	Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study). Trials, 2022, 23, 119.	0.7	6
12	Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells. Gastric Cancer, 2022, 25, 558-572.	2.7	14
13	Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Annals of Surgery, 2022, 275, 1043-1049.	2.1	47
14	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer, 2022, 25, 619-628.	2.7	18
15	ASO Author Reflections: Optimized Cutoff Value of Albumin–Bilirubin Score to Predict Prognosis of Patients with Esophageal Squamous Cell Carcinoma After Radical Resection. Annals of Surgical Oncology, 2022, , 1.	0.7	Ο
16	Prognostic Value of a Modified Albumin–Bilirubin Score Designed for Patients with Esophageal Squamous Cell Carcinoma After Radical Resection. Annals of Surgical Oncology, 2022, 29, 4889-4896.	0.7	7
17	Expression of cellular retinoic acid binding protein 1 predicts peritoneal recurrence of gastric cancer. International Journal of Oncology, 2022, 60, .	1.4	4
18	Transcriptomic profiling on localized gastric cancer identified CPLX1 as a gene promoting malignant phenotype of gastric cancer and a predictor of recurrence after surgery and subsequent chemotherapy. Journal of Gastroenterology, 2022, 57, 640-653.	2.3	2

#	Article	IF	CITATIONS
19	Genomewide Expression Profiling Identifies a Novel miRNA-based Signature for the Detection of Peritoneal Metastasis in Patients With Gastric Cancer. Annals of Surgery, 2021, 274, e425-e434.	2.1	25
20	Preoperative risk factors for postoperative intra-abdominal infectious complication after gastrectomy for gastric cancer using a Japanese web-based nationwide database. Gastric Cancer, 2021, 24, 205-213.	2.7	16
21	Impact of Qualitative and Quantitative Biliary Contamination Status on the Incidence of Postoperative Infection Complications in Patients Undergoing Pancreatoduodenectomy. Annals of Surgical Oncology, 2021, 28, 560-569.	0.7	4
22	High Serum Uric Acid Levels Could Be a Risk Factor of Hepatocellular Carcinoma Recurrences. Nutrition and Cancer, 2021, 73, 996-1003.	0.9	6
23	Newly developed primary malignancies in long-term survivors who underwent curative esophagectomy for squamous cell carcinoma of the esophagus. Surgery Today, 2021, 51, 153-158.	0.7	2
24	Short-term outcomes of gastrectomy after neoadjuvant chemotherapy for clinical stage III gastric cancer: propensity score-matched analysis of a multi-institutional database. Surgery Today, 2021, 51, 821-828.	0.7	4
25	Survival analysis of a prospective multicenter observational study on surgical palliation among patients receiving treatment for malignant gastric outlet obstruction caused by incurable advanced gastric cancer. Gastric Cancer, 2021, 24, 224-231.	2.7	10
26	Multicenter randomized phase II trial of prophylactic rightâ€half dissection of superior mesenteric artery nerve plexus in pancreatoduodenectomy for pancreatic head cancer. Annals of Gastroenterological Surgery, 2021, 5, 111-118.	1.2	10
27	Impact of Preoperative Occult-Bacterial Translocation on Surgical Site Infection in Patients Undergoing Pancreatoduodenectomy. Journal of the American College of Surgeons, 2021, 232, 298-306.	0.2	10
28	Randomised phase II trial of capecitabine plus oxaliplatinÂwith continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study). European Journal of Cancer, 2021, 144, 61-71.	1.3	3
29	Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 2277-2286.	0.7	11
30	Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy. Pancreas, 2021, 50, 37-46.	0.5	0
31	Transcriptomic Profiling Identifies a Risk Stratification Signature for Predicting Peritoneal Recurrence and Micrometastasis in Gastric Cancer. Clinical Cancer Research, 2021, 27, 2292-2300.	3.2	17
32	Hepatic metastasis of gastric cancer is associated with enhanced expression of ethanolamine kinase 2 via the p53–Bcl-2 intrinsic apoptosis pathway. British Journal of Cancer, 2021, 124, 1449-1460.	2.9	17
33	Oncolytic herpes simplex virus <scp>HF10</scp> (canerpaturev) promotes accumulation of <scp>CD8</scp> ⁺ <scp>PD</scp> â€1 ^{â^'} tumorâ€infiltrating T cells in <scp>PDâ€L1</scp> â€enriched tumor microenvironment. International Journal of Cancer, 2021, 149, 214-227.	2.3	13
34	C-protein subunit gamma-4 expression has potential for detection, prediction and therapeutic targeting in liver metastasis of gastric cancer. British Journal of Cancer, 2021, 125, 220-228.	2.9	13
35	Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. Journal of Gastrointestinal Oncology, 2021, 12, S110-S117.	0.6	14
36	Safety of Combined Division vs Separate Division of the Splenic Vein in Patients Undergoing Distal Pancreatectomy. JAMA Surgery, 2021, 156, 418.	2.2	4

#	Article	IF	CITATIONS
37	Comparison of effects of six main gastrectomy procedures on patients' quality of life assessed by Postgastrectomy Syndrome Assessment Scale-45. World Journal of Gastrointestinal Surgery, 2021, 13, 461-475.	0.8	15
38	Accurate Prediction of Prognosis After Radical Resection of Gastric Cancer by the Modified Systemic Inflammation Score; a Multicenter Dataset Analysis. World Journal of Surgery, 2021, 45, 2513-2520.	0.8	6
39	C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cells. Cells, 2021, 10, 1502.	1.8	6
40	Blockade of CHRNB2 signaling with a therapeutic monoclonal antibody attenuates the aggressiveness of gastric cancer cells. Oncogene, 2021, 40, 5495-5504.	2.6	12
41	Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. Hepatology International, 2021, 15, 1278-1287.	1.9	16
42	ISOlation Procedure vs. conventional procedure during Distal Pancreatectomy (ISOP-DP trial): study protocol for a randomized controlled trial. Trials, 2021, 22, 633.	0.7	1
43	Processing and Thermal Conductivity of Bulk Nanocrystalline Aluminum Nitride. Materials, 2021, 14, 5565.	1.3	1
44	The impact of chronic Epstein–Barr virus infection on the liver graft of pediatric liver transplant recipients: A retrospective observational study. Transplant Infectious Disease, 2021, 23, e13731.	0.7	1
45	Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy. Clinical Epigenetics, 2021, 13, 172.	1.8	1
46	Limited resection vs. pancreaticoduodenectomy for primary duodenal adenocarcinoma: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2021, 26, 450-460.	1.0	13
47	The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer. Surgery Today, 2021, 51, 1099-1107.	0.7	5
48	Pancreatic Fat and Body Composition Measurements by Computed Tomography are Associated with Pancreatic Fistula After Pancreatectomy. Annals of Surgical Oncology, 2021, 28, 530-538.	0.7	27
49	Update on molecular biomarkers for diagnosis and prediction of prognosis and treatment responses in gastric cancer. Histology and Histopathology, 2021, 36, 817-832.	0.5	3
50	Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer. Cancers, 2021, 13, 36.	1.7	12
51	Synaptotagmin 13 Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer. Current Oncology, 2021, 28, 4080-4092.	0.9	3
52	Platelet isoform of phosphofructokinase accelerates malignant features in breast cancer. Oncology Reports, 2021, 47, .	1.2	9
53	Intraperitoneal Chemotherapy as Adjuvant or Perioperative Chemotherapy for Patients with Type 4 Scirrhous Gastric Cancer: PHOENIX-GC2 Trial. Journal of Clinical Medicine, 2021, 10, 5666.	1.0	8
54	Defecation disorders are crucial sequelae that impairs the quality of life of patients after conventional gastrectomy. World Journal of Gastrointestinal Surgery, 2021, 13, 1484-1496.	0.8	0

#	Article	IF	CITATIONS
55	Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial. Contemporary Clinical Trials Communications, 2021, 24, 100853.	0.5	0
56	First- and second-order magnetic anisotropy and damping of europium iron garnet under high strain. Physical Review Materials, 2021, 5, .	0.9	11
57	S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model Nagoya Journal of Medical Science, 2021, 83, 683-696.	0.6	2
58	Preoperative six-minute walk distance as a predictor of postoperative complication in patients with esophageal cancer. Ecological Management and Restoration, 2020, 33, .	0.2	14
59	Detection of indocyanine green fluorescence to determine tumor location during laparoscopic gastrectomy for gastric cancer: Results of a prospective study. Asian Journal of Endoscopic Surgery, 2020, 13, 160-167.	0.4	15
60	The Preoperative Prognostic Nutritional Index Predicts Short-Term and Long-Term Outcomes of Patients with Stage II/III Gastric Cancer: Analysis of a Multi-Institution Dataset. Digestive Surgery, 2020, 37, 135-144.	0.6	36
61	Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II). International Journal of Clinical Oncology, 2020, 25, 118-125.	1.0	6
62	Tumor size  ≥50Âmm as an Independent Prognostic Factor for Patients with Stage II or III Gastric Cancer After Postoperative Sâ€1ÂMonotherapy: Analysis of a Multiâ€institution Dataset. World Journal of Surgery, 2020, 44, 194-201.	0.8	4
63	Fraser extracellular matrix complex subunit 1 promotes liver metastasis of gastric cancer. International Journal of Cancer, 2020, 146, 2865-2876.	2.3	18
64	Serum levels of ANOS1 serve as a diagnostic biomarker of gastric cancer: a prospective multicenter observational study. Gastric Cancer, 2020, 23, 203-211.	2.7	29
65	Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition. International Journal of Clinical Oncology, 2020, 25, 217-239.	1.0	17
66	Prognosis After Laparoscopic Gastrectomy in Patients with Pathological Stage II or III Gastric Cancer Who Were Preoperatively Diagnosed with Clinical Stage I: Propensity Score Matching Analysis of a Multicenter Dataset. Annals of Surgical Oncology, 2020, 27, 268-275.	0.7	2
67	Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis. Oncology, 2020, 98, 48-52.	0.9	5
68	A message from the new editor-in-chief. Gastric Cancer, 2020, 23, 1-2.	2.7	2
69	Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 2081-2089.	0.7	12
70	PRAME as a Potential Biomarker for Liver Metastasis of Gastric Cancer. Annals of Surgical Oncology, 2020, 27, 2071-2080.	0.7	13
71	Optimized Cutoff Value of Serum Squamous Cell Carcinoma Antigen Concentration Accurately Predicts Recurrence After Curative Resection of Squamous Cell Carcinoma of the Esophagus. Annals of Surgical Oncology, 2020, 27, 1233-1240.	0.7	14
72	Clinical impact of additional therapy for residual pancreatic cancer. Surgery Today, 2020, 50, 440-448.	0.7	1

#	Article	IF	CITATIONS
73	ASO Author Reflections: The Naples Prognostic Score Predicts Long-Term Survival in Patients with Resected Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 896-897.	0.7	0
74	Clinical Implications of Naples Prognostic Score in Patients with Resected Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 887-895.	0.7	50
75	The Significance of Molecular Biomarkers on Clinical Survival Outcome Differs Depending on Colon Cancer Sidedness. Anticancer Research, 2020, 40, 201-211.	0.5	2
76	Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models. Anti-Cancer Drugs, 2020, 31, 241-250.	0.7	4
77	What is the impact of systemic chemotherapy for lateral lymph nodes in patients with locally advanced low rectal cancer?. International Journal of Colorectal Disease, 2020, 35, 2073-2080.	1.0	2
78	Is there disparity between regions and facilities in surgical resident training in Japan? Insights from a national survey. Surgery Today, 2020, 50, 1585-1593.	0.7	2
79	No Significant Effect of Daikenchuto (TJ-100) on Peritoneal IL-9 and IFN-γ Levels After Pancreaticoduodenectomy. Clinical and Experimental Gastroenterology, 2020, Volume 13, 461-466.	1.0	Ο
80	ASO Author Reflections: Characteristics Associated with Nodal and Distant Recurrence After Radical Esophagectomy for Squamous Cell Carcinoma of the Thoracic Esophagus. Annals of Surgical Oncology, 2020, 27, 3206-3207.	0.7	0
81	STRA6 Expression Serves as a Prognostic Biomarker of Gastric Cancer. Cancer Genomics and Proteomics, 2020, 17, 509-516.	1.0	9
82	Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer. Molecular Cancer, 2020, 19, 131.	7.9	48
83	Accurate Risk Stratification of Patients with Nodeâ€Positive Gastric Cancer by Lymph Node Ratio. World Journal of Surgery, 2020, 44, 4184-4192.	0.8	8
84	Amido-Bridged Nucleic Acid-Modified Antisense Oligonucleotides Targeting SYT13 to Treat Peritoneal Metastasis of Gastric Cancer. Molecular Therapy - Nucleic Acids, 2020, 22, 791-802.	2.3	30
85	Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preoperative therapy. Journal of Hepato-Biliary-Pancreatic Sciences, 2020, 27, 487-495.	1.4	7
86	An outcome analysis of predictive factors for portal or splenic vein thrombosis after distal pancreatectomy. Surgery Today, 2020, 50, 1282-1289.	0.7	4
87	ASO Authors Reflections: Preoperative Pancreatic Fat and Body Composition Measurements Influence the Incidence of Grade B/C Postoperative Pancreatic Fistula After Pancreatectomy. Annals of Surgical Oncology, 2020, 27, 746-747.	0.7	1
88	Comparison of Postoperative Quality of Life among Three Different Reconstruction Methods After Proximal Gastrectomy: Insights From the PGSAS Study. World Journal of Surgery, 2020, 44, 3433-3440.	0.8	13
89	Survival times are similar among patients with peritoneal, hematogenous, and nodal recurrences after curative resections for gastric cancer. Cancer Medicine, 2020, 9, 5392-5399.	1.3	6
90	An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus. Oncologist, 2020, 25, e1650-e1654.	1.9	7

#	Article	IF	CITATIONS
91	Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303). International Journal of Clinical Oncology, 2020, 25, 1793-1799.	1.0	2
92	Pelvic exenteration associated with future renal dysfunction. Surgery Today, 2020, 50, 1601-1609.	0.7	1
93	Characteristics of Lung Metastasis as an Initial Recurrence Pattern After Curative Resection of Pancreatic Cancer. Pancreas, 2020, 49, 699-705.	0.5	8
94	Are graduating residents sufficiently competent? Results of a national gap analysis survey of program directors and graduating residents in Japan. Surgery Today, 2020, 50, 995-1001.	0.7	7
95	Chromobox 2 Expression Predicts Prognosis After Curative Resection of Oesophageal Squamous Cell Carcinoma. Cancer Genomics and Proteomics, 2020, 17, 391-400.	1.0	6
96	KCNJ15 Expression and Malignant Behavior of Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 2559-2568.	0.7	11
97	Propensity-score-matched analysis of a multi-institutional dataset to compare postoperative complications between Billroth I and Roux-en-Y reconstructions after distal gastrectomy. Gastric Cancer, 2020, 23, 734-745.	2.7	18
98	Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. Journal of Gastroenterology, 2020, 55, 653-661.	2.3	38
99	Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. International Journal of Clinical Oncology, 2020,	1.0	19
100	25, 403-417. Clinical characteristics and surgical outcomes of retroperitoneal tumors: a comprehensive data collection from multiple departments. International Journal of Clinical Oncology, 2020, 25, 929-936.	1.0	14
101	Treatment option of endoscopic stent insertion or gastrojejunostomy for gastric outlet obstruction due to gastric cancer: a propensity score-matched analysis. Gastric Cancer, 2020, 23, 667-676.	2.7	20
102	Importance of the neoadjuvant rectal (NAR) score to the outcome of neoadjuvant chemotherapy alone for locally advanced rectal cancer. Surgery Today, 2020, 50, 912-919.	0.7	7
103	Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. British Journal of Cancer, 2020, 122, 771-777.	2.9	48
104	Systemic Inflammation Score as a Predictor of Pneumonia after Radical Resection of Gastric Cancer: Analysis of a Multi-Institutional Dataset. Digestive Surgery, 2020, 37, 401-410.	0.6	12
105	ASO Author Reflections: KCNJ15 Expression and Malignant Behavior of Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 2569-2570.	0.7	0
106	Expression and Malignant Potential of B4GALNT4 in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 3247-3256.	0.7	9
107	JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Annals of Oncology, 2020, 31, 861-872.	0.6	94
108	ASO Author Reflections: Expression and Malignant Potential of B4GALNT4 in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 3257-3258.	0.7	0

#	Article	IF	CITATIONS
109	Characteristics Associated with Nodal and Distant Recurrence After Radical Esophagectomy for Squamous Cell Carcinoma of the Thoracic Esophagus. Annals of Surgical Oncology, 2020, 27, 3195-3205.	0.7	11
110	Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. Anticancer Research, 2020, 40, 1843-1853.	0.5	12
111	MZB1 expression indicates poor prognosis in estrogen receptor‑positive breast cancer. Oncology Letters, 2020, 20, 1-1.	0.8	14
112	Association between Lymphovascular Invasion and Recurrence in Patients with pT1N+ or pT2–3N0 Gastric Cancer: a Multi-institutional Dataset Analysis. Journal of Gastric Cancer, 2020, 20, 41.	0.9	9
113	Is the measurement of drain amylase content useful for predicting pancreas-related complications after gastrectomy with systematic lymphadenectomy?. World Journal of Gastroenterology, 2020, 26, 1594-1600.	1.4	7
114	D2 lymph node dissection confers little benefit on the overall survival of older patients with resectable gastric cancer: a propensity score-matching analysis of a multi-institutional dataset. Surgery Today, 2020, 50, 1434-1442.	0.7	9
115	A prospective trial to evaluate treatment effects of a β-hydroxy-β-methylbutyrate containing nutrient for leakage at the anastomotic site after esophagectomy. Nagoya Journal of Medical Science, 2020, 82, 33-37.	0.6	0
116	The efficacy of oxaliplatin combination adjuvant chemotherapy for elderly patients with stage III colorectal cancer. Nagoya Journal of Medical Science, 2020, 82, 603-611.	0.6	0
117	A comprehensive methylation signature identifies lymph node metastasis in esophageal squamous cell carcinoma. International Journal of Cancer, 2019, 144, 1160-1169.	2.3	10
118	Intratumoral <i>Fusobacterium Nucleatum</i> Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma. Clinical Cancer Research, 2019, 25, 6170-6179.	3.2	104
119	Incorporating molecular biomarkers into clinical practice for gastric cancer. Expert Review of Anticancer Therapy, 2019, 19, 757-771.	1.1	11
120	Splenectomy in living donor liver transplantation and risk factors of portal vein thrombosis. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 337-342.	0.6	17
121	Multiâ€institutional analysis of the prognostic significance of postoperative complications after curative resection for gastric cancer. Cancer Medicine, 2019, 8, 5194-5201.	1.3	32
122	Recent advances in molecular biomarkers for patients with hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2019, 19, 725-738.	1.5	15
123	Comparison of nonâ€invasive liver reserve and fibrosis models: Implications for surgery and prognosis for hepatocellular carcinoma. Hepatology Research, 2019, 49, 1305-1315.	1.8	12
124	Dynamics of Circulating Tumor Cells Early After Targeting Therapy to Human EGFR-mutated Lung Cancers and HER2 Gene-amplified Gastric Cancers in Mice. Anticancer Research, 2019, 39, 4711-4720.	0.5	5
125	Feasibility of subtotal esophagectomy with systematic lymphadenectomy in selected elderly patients with esophageal cancer; a propensity score matching analysis. BMC Surgery, 2019, 19, 143.	0.6	24
126	Modified Systemic Inflammation Score is Useful for Risk Stratification After Radical Resection of Squamous Cell Carcinoma of the Esophagus. Annals of Surgical Oncology, 2019, 26, 4773-4781.	0.7	19

#	Article	IF	CITATIONS
127	Establishment of Peritoneal and Hepatic Metastasis Mouse Xenograft Models Using Gastric Cancer Cell Lines. In Vivo, 2019, 33, 1785-1792.	0.6	18
128	<i>PRAME</i> Expression as a Potential Biomarker for Hematogenous Recurrence of Esophageal Squamous Cell Carcinoma. Anticancer Research, 2019, 39, 5943-5951.	0.5	9
129	Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer. Anticancer Research, 2019, 39, 5903-5910.	0.5	9
130	Level of Melanotransferrin in Tissue and Sera Serves as a Prognostic Marker of Gastric Cancer. Anticancer Research, 2019, 39, 6125-6133.	0.5	15
131	Expression, Function, and Prognostic Value of MACE-D4 Protein in Esophageal Squamous Cell Carcinoma. Anticancer Research, 2019, 39, 6015-6023.	0.5	5
132	Homeobox C10 Influences on the Malignant Phenotype of Gastric Cancer Cell Lines and its Elevated Expression Positively Correlates with Recurrence and Poor Survival. Annals of Surgical Oncology, 2019, 26, 1535-1543.	0.7	16
133	Risk Prediction of Postoperative Pneumonia After Subtotal Esophagectomy Based on Preoperative Serum Cholinesterase Concentrations. Annals of Surgical Oncology, 2019, 26, 3718-3726.	0.7	27
134	Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth. Molecular Therapy - Oncolytics, 2019, 13, 107-115.	2.0	17
135	Novel implications of combined arterial resection for locally advanced pancreatic cancer in the era of newer chemo-regimens. European Journal of Surgical Oncology, 2019, 45, 1895-1900.	0.5	13
136	A snapshot of surgical resident training in Japan: results of a national-level needs assessment survey. Surgery Today, 2019, 49, 870-876.	0.7	11
137	The levels of SYT13 and CEA mRNAs in peritoneal lavages predict the peritoneal recurrence of gastric cancer. Gastric Cancer, 2019, 22, 1143-1152.	2.7	31
138	Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer. Hpb, 2019, 21, 1211-1218.	0.1	19
139	Effects of duration of initial treatment on postoperative complications in pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2019, 26, 235-241.	1.4	6
140	Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset. Gastric Cancer, 2019, 22, 1215-1225.	2.7	39
141	Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. Journal of Clinical Oncology, 2019, 37, 1296-1304.	0.8	258
142	A genomewide transcriptomic approach identifies a novel gene expression signature for the detection of lymph node metastasis in patients with early stage gastric cancer. EBioMedicine, 2019, 41, 268-275.	2.7	18
143	Proposal of a Scoring Scale to Estimate Risk of the Discontinuation of Sâ€1 Adjuvant Monotherapy in Patients with Stage II to III Gastric Cancer: A Multiâ€Institutional Dataset Analysis. World Journal of Surgery, 2019, 43, 2016-2024.	0.8	6
144	Detection of circulating tumor cells in drainage venous blood from colorectal cancer patients using a new filtration and cytology-based automated platform. PLoS ONE, 2019, 14, e0212221.	1.1	18

#	Article	IF	CITATIONS
145	CRMP5-associated GTPase (<i>CRAG</i>) Is a Candidate Driver Gene for Colorectal Cancer Carcinogenesis. Anticancer Research, 2019, 39, 99-106.	0.5	11
146	Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy. Journal of Translational Medicine, 2019, 17, 1.	1.8	189
147	The Controlling Nutritional Status Score Serves as a Predictor of Short- and Long-Term Outcomes for Patients with Stage 2 or 3 Gastric Cancer: Analysis of a Multi-institutional Data Set. Annals of Surgical Oncology, 2019, 26, 456-464.	0.7	61
148	Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer. Annals of Surgical Oncology, 2019, 26, 836-844.	0.7	22
149	Intraoperative Blood Loss is Associated with Shortened Postoperative Survival of Patients with Stage II/III Gastric Cancer: Analysis of a Multiâ€institutional Dataset. World Journal of Surgery, 2019, 43, 870-877.	0.8	32
150	Long-term quality of life and nutrition status of the aboral pouch reconstruction after total gastrectomy for gastric cancer: a prospective multicenter observational study (CCOG1505). Gastric Cancer, 2019, 22, 607-616.	2.7	21
151	Perioperative and prognostic implication of albuminâ€bilirubinâ€ <scp>TNM</scp> score in Childâ€Pugh class A hepatocellular carcinoma. Annals of Gastroenterological Surgery, 2019, 3, 65-74.	1.2	12
152	Surgical risk and benefits of laparoscopic surgery for elderly patients with gastric cancer: a multicenter prospective cohort study. Gastric Cancer, 2019, 22, 845-852.	2.7	28
153	Number of retrieved lymph nodes is an independent prognostic factor after total gastrectomy for patients with stage III gastric cancer: propensity score matching analysis of a multi-institution dataset. Gastric Cancer, 2019, 22, 853-863.	2.7	32
154	Genome-wide Discovery of a Novel Gene-expression Signature for the Identification of Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma. Annals of Surgery, 2019, 269, 879-886.	2.1	11
155	Introducing laparoscopic total gastrectomy for gastric cancer in general practice: a retrospective cohort study based on a nationwide registry database in Japan. Gastric Cancer, 2019, 22, 202-213.	2.7	88
156	Optical trocar access for initial trocar placement in laparoscopic gastrointestinal surgery: <scp>A</scp> propensity scoreâ€matching analysis. Asian Journal of Endoscopic Surgery, 2019, 12, 37-42.	0.4	7
157	Long-lasting discussion: Adverse effects of intraoperative blood loss and allogeneic transfusion on prognosis of patients with gastric cancer. World Journal of Gastroenterology, 2019, 25, 2743-2751.	1.4	38
158	Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer. World Journal of Gastrointestinal Oncology, 2019, 11, 17-27.	0.8	22
159	Albumin-Bilirubin Score Predicts Tolerability to Adjuvant S-1 Monotherapy after Curative Gastrectomy. Journal of Gastric Cancer, 2019, 19, 183.	0.9	12
160	A case of renal salt-wasting syndrome induced by cisplatin and 5-FU during treatment of esophageal squamous cell carcinoma. Annals of Cancer Research and Therapy, 2019, 27, 64-66.	0.1	0
161	Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study. Nagoya Journal of Medical Science, 2019, 81, 233-239.	0.6	3
162	Postoperative adalimumab maintenance therapy for Japanese patients with Crohn's disease: a single-center, single-arm phase II trial (CCOG-1107 study). Surgery Today, 2018, 48, 609-617.	0.7	7

#	Article	IF	CITATIONS
163	A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial. Gastric Cancer, 2018, 21, 811-818.	2.7	11
164	Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 815-821.	1.1	21
165	Troponin I2 as a Specific Biomarker for Prediction of Peritoneal Metastasis in Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 2083-2090.	0.7	32
166	Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma. Clinical Nuclear Medicine, 2018, 43, 482-485.	0.7	15
167	Surgical outcomes of laparoscopic distal gastrectomy compared to open distal gastrectomy: A retrospective cohort study based on a nationwide registry database in Japan. Annals of Gastroenterological Surgery, 2018, 2, 55-64.	1.2	51
168	A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial. Gastric Cancer, 2018, 21, 1014-1023.	2.7	34
169	Significance of Preoperative Systemic Inflammation Score in Shortâ€Term and Longâ€Term Outcomes of Patients with Pathological T2–4 Gastric Cancer After Radical Gastrectomy. World Journal of Surgery, 2018, 42, 3277-3285.	0.8	29
170	Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer. Annals of Surgery, 2018, 267, 495-503.	2.1	81
171	Perioperative Serum Carcinoembryonic Antigen Levels Predict Recurrence and Survival of Patients with Pathological T2-4 Gastric Cancer Treated with Curative Gastrectomy. Digestive Surgery, 2018, 35, 55-63.	0.6	28
172	Nutritional Recovery after Open and Laparoscopic Distal Gastrectomy for Early Gastric Cancer: A Prospective Multicenter Comparative Trial (CCOG1204). Digestive Surgery, 2018, 35, 11-18.	0.6	7
173	Acute phase dynamics of circulating tumor cells after paclitaxel and doxorubicin chemotherapy in breast cancer mouse models. Breast Cancer Research and Treatment, 2018, 167, 439-450.	1.1	15
174	Higher incidence of pancreatic fistula in laparoscopic gastrectomy. Real-world evidence from a nationwide prospective cohort study. Gastric Cancer, 2018, 21, 162-170.	2.7	83
175	Morbidity and mortality from a propensity score-matched, prospective cohort study of laparoscopic versus open total gastrectomy for gastric cancer: data from a nationwide web-based database. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 2766-2773.	1.3	54
176	Effect of Plasma-Activated Lactated Ringer's Solution on Pancreatic Cancer Cells In Vitro and In Vivo. Annals of Surgical Oncology, 2018, 25, 299-307.	0.7	70
177	Gastric venous congestion and bleeding in association with total pancreatectomy. Journal of Hepato-Biliary-Pancreatic Sciences, 2018, 25, 150-154.	1.4	17
178	Preoperative Albumin–Bilirubin Grade Predicts Recurrences After Radical Gastrectomy in Patients with pT2â€4 Gastric Cancer. World Journal of Surgery, 2018, 42, 773-781.	0.8	40
179	Synthesis, processing and transport properties of cubic and trigonal solid solutions in the Mg-Si-Sn system. Journal of Alloys and Compounds, 2018, 735, 741-749.	2.8	4
180	Clinical effectiveness of geriatric assessment for predicting the tolerability of outpatient chemotherapy in older adults with cancer. Journal of Geriatric Oncology, 2018, 9, 84-86.	0.5	5

#	Article	IF	CITATIONS
181	Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial. Journal of Clinical Oncology, 2018, 36, 1922-1929.	0.8	245
182	Background factors influencing postgastrectomy syndromes after various types of gastrectomy. World Journal of Clinical Cases, 2018, 6, 1111-1120.	0.3	16
183	Essential points for revisions in the guidelines of the JPS 7 th edition and new resectability criteria in pancreatic cancer. Suizo, 2018, 33, 12-17.	0.1	0
184	Pathological tumor infiltrative pattern and sites of initial recurrence in stage II/III gastric cancer: Propensity score matching analysis of a multiâ€institutional dataset. Cancer Medicine, 2018, 7, 6020-6029.	1.3	14
185	Dualâ€center randomized clinical trial exploring the optimal duration of antimicrobial prophylaxis in patients undergoing pancreaticoduodenectomy following biliary drainage. Annals of Gastroenterological Surgery, 2018, 2, 442-450.	1.2	15
186	Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification. Pancreas, 2018, 47, 1350-1356.	0.5	8
187	RASEF expression correlates with hormone receptor status in breast cancer. Oncology Letters, 2018, 16, 7223-7230.	0.8	3
188	Systematic control of strain-induced perpendicular magnetic anisotropy in epitaxial europium and terbium iron garnet thin films. APL Materials, 2018, 6, .	2.2	44
189	Significance of Lysyl oxidase‑likeÃ ⁻ ¿½22 gene expression on the epithelial‑mesenchymal status of hepatocellular carcinoma. Oncology Reports, 2018, 39, 2664-2672.	1.2	12
190	Copine�5 expression predicts prognosis following curative resection of esophageal squamous cell carcinoma. Oncology Reports, 2018, 40, 3772-3780.	1.2	11
191	The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers. Cancers, 2018, 10, 356.	1.7	123
192	Cutting-edge evidence of adjuvant treatments for gastric cancer. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1109-1122.	1.4	3
193	Transition of serum cytokines following pancreaticoduodenectomy: A subsidiary study of JAPAN‑PD. Oncology Letters, 2018, 16, 6847-6853.	0.8	1
194	Emerging evidence of the molecular landscape specific for hematogenous metastasis from gastric cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 124-136.	0.8	18
195	Expression of sushi domain containing two reflects the malignant potential of gastric cancer. Cancer Medicine, 2018, 7, 5194-5204.	1.3	19
196	Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms. Pancreas, 2018, 47, 974-979.	0.5	23
197	Impact of the Controlling Nutritional Status Score on the Prognosis After Curative Resection of Pancreatic Ductal Adenocarcinoma. Pancreas, 2018, 47, 823-829.	0.5	36
198	A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer, 2018, 18, 596.	1.1	110

#	Article	IF	CITATIONS
199	Clinical practice guidance for nextâ€generation sequencing in cancer diagnosis and treatment (Edition) Tj ETQq1	1,0,78431 1.7	4ൃgBT /Ov
200	Pattern-Specific Transcriptomics Identifies <i>ASGR2</i> as a Predictor of Hematogenous Recurrence of Gastric Cancer. Molecular Cancer Research, 2018, 16, 1420-1429.	1.5	12
201	SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells. Oncogene, 2018, 37, 5355-5366.	2.6	55
202	Gain in polycrystalline Nd-doped alumina: leveraging length scales to create a new class of high-energy, short pulse, tunable laser materials. Light: Science and Applications, 2018, 7, 33.	7.7	64
203	Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer. Scientific Reports, 2018, 8, 9846.	1.6	29
204	Splenic vein resection together with the pancreatic parenchyma versus separated resection after isolation of the parenchyma during distal pancreatectomy (COSMOS-DP trial): study protocol for a randomised controlled trial. Trials, 2018, 19, 369.	0.7	8
205	Overexpression of <i>FGFR1</i> Promotes Peritoneal Dissemination <i>Via</i> Epithelial-to-Mesenchymal Transition in Gastric Cancer. Cancer Genomics and Proteomics, 2018, 15, 313-320.	1.0	15
206	Surgery with curative intent for stage IV gastric cancer: Is it a reality of illusion?. Annals of Gastroenterological Surgery, 2018, 2, 339-347.	1.2	16
207	A novel dualâ€marker expression panel for easy and accurate risk stratification of patients with gastric cancer. Cancer Medicine, 2018, 7, 2463-2471.	1.3	10
208	Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer. Annals of Surgical Oncology, 2018, 25, 3365-3371.	0.7	27
209	Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study). Oncologist, 2018, 23, 919-927.	1.9	13
210	Review of recent efforts to discover biomarkers for early detection, monitoring, prognosis, and prediction of treatment responses of patients with gastric cancer. Expert Review of Gastroenterology and Hepatology, 2018, 12, 657-670.	1.4	38
211	Review of recent molecular landscape knowledge of gastric cancer. Histology and Histopathology, 2018, 33, 11-26.	0.5	38
212	Emerging evidence of molecular biomarkers in hepatocellular carcinoma. Histology and Histopathology, 2018, 33, 343-355.	0.5	14
213	Integrated multigene expression panel to prognosticate patients with gastric cancer. Oncotarget, 2018, 9, 18775-18785.	0.8	8
214	Intense photoluminescence and optical gain in rare-earth doped Polycrystalline Sapphire: a new bulk media for high-power phosphors and high-energy lasers. , 2018, , .		0
215	Synthesis and ferrimagnetic properties of Y3(1-x)Tm3xFe5O12 powders. , 2018, , .		Ο
216	Preparation of yttria-dtabilized nanocrystalline zirconia with tunable optical properties. , 2018, , .		0

#	Article	IF	CITATIONS
217	Obesity does not affect peri- and postoperative outcomes of transabdominal laparoscopic adrenalectomy. Nagoya Journal of Medical Science, 2018, 80, 21-28.	0.6	14
218	<editors' choice=""> Efficacy of enteral nutrients containing β-hydroxy-β-methylbutyrate, glutamine, and arginine for the patients with anastomotic leakage after gastrectomy: study protocol of a multicenter phase II clinical trial. Nagoya Journal of Medical Science, 2018, 80, 351-355.</editors'>	0.6	3
219	Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial. Gastric Cancer, 2017, 20, 190-199.	2.7	27
220	Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting. Journal of Gastroenterology, 2017, 52, 81-93.	2.3	51
221	Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. Annals of Surgery, 2017, 265, 397-401.	2.1	86
222	The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy. International Journal of Oncology, 2017, 50, 381-386.	1.4	26
223	Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study. International Journal of Surgery, 2017, 39, 45-51.	1.1	74
224	Negative regulation of HLA-DR expression on endothelial cells by anti-blood group A/B antibody ligation and mTOR inhibition. Transplant Immunology, 2017, 40, 22-30.	0.6	12
225	Intraperitoneal Administration of Plasma-Activated Medium: Proposal of a Novel Treatment Option for Peritoneal Metastasis From Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 1188-1194.	0.7	74
226	Stapling an extracorporeal Billrothâ€l anastomosis by the complete double stapling technique after laparoscopyâ€essisted distal gastrectomy. Asian Journal of Endoscopic Surgery, 2017, 10, 137-142.	0.4	1
227	Gastric cancer treated by endoscopic submucosal dissection or endoscopic mucosal resection in Japan from 2004 through 2006: JGCA nationwide registry conducted in 2013. Gastric Cancer, 2017, 20, 834-842.	2.7	48
228	The Charlson age comorbidity index predicts prognosis in patients with resected pancreatic cancer. International Journal of Surgery, 2017, 39, 169-175.	1.1	35
229	Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan. Surgery Today, 2017, 47, 899-907.	0.7	20
230	GPR155 Serves as a Predictive Biomarker for Hematogenous Metastasis in Patients with Gastric Cancer. Scientific Reports, 2017, 7, 42089.	1.6	24
231	Epigenetic modulation associated with carcinogenesis and prognosis of human gastric cancer. Oncology Letters, 2017, 13, 3363-3368.	0.8	14
232	Expression of regulatory factor X1 can predict the prognosis of breast cancer. Oncology Letters, 2017, 13, 4334-4340.	0.8	6
233	Usefulness of endoscopic ultrasonographyâ€elastography as a predictive tool for the occurrence of pancreatic fistula after pancreatoduodenectomy. Journal of Hepato-Biliary-Pancreatic Sciences, 2017, 24, 649-656.	1.4	22
234	<i>PAX5</i> gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma. Epigenetics, 2017, 12, 865-874.	1.3	21

#	Article	IF	CITATIONS
235	The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902). BMC Cancer, 2017, 17, 243.	1.1	13
236	Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. Surgery, 2017, 162, 784-791.	1.0	27
237	Usefulness of preoperative estimated glomerular filtration rate to predict complications after curative gastrectomy in patients with clinical T2–4 gastric cancer. Gastric Cancer, 2017, 20, 736-743.	2.7	19
238	Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Gastric Cancer, 2017, 20, 111-121.	2.7	64
239	FAM46C Serves as a Predictor of Hepatic Recurrence in Patients with Resectable Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 3438-3445.	0.7	39
240	Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane†and trastuzumabâ€naÃ⁻ve patients with HER2â€positive, previously treated, advanced, or recurrent gastric cancer (JFMC45â€1102). International Journal of Cancer, 2017, 140, 188-196.	2.3	27
241	Proposal of the Coagulation Score as a Predictor for Short-Term and Long-Term Outcomes of Patients with Resectable Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 502-509.	0.7	46
242	Multi-institutional prospective feasibility study to explore tolerability and efficacy of oral nutritional supplements for patients with gastric cancer undergoing gastrectomy (CCOG1301). Gastric Cancer, 2017, 20, 718-727.	2.7	45
243	Identification of NCCRP1 as an epigenetically regulated tumor suppressor and biomarker for malignant phenotypes of squamous cell carcinoma of the esophagus. Oncology Letters, 2017, 14, 4822-4828.	0.8	15
244	Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials. Frontiers in Oncology, 2017, 7, 149.	1.3	75
245	Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity. Oncolytic Virotherapy, 2017, Volume 6, 31-38.	6.0	9
246	Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma. BMC Cancer, 2017, 17, 610.	1.1	15
247	Prognostic Value of Long Non-Coding RNA HULC and MALAT1 Following the Curative Resection of Hepatocellular Carcinoma. Scientific Reports, 2017, 7, 16142.	1.6	24
248	FBXO50 Enhances the Malignant Behavior of Gastric Cancer Cells. Annals of Surgical Oncology, 2017, 24, 3771-3779.	0.7	19
249	Clinical implication of Frizzled 2 expression and its association with epithelial-to-mesenchymal transition in hepatocellular carcinoma. International Journal of Oncology, 2017, 50, 1647-1654.	1.4	20
250	Overexpression of Derlin 3 is associated with malignant phenotype of breast cancer cells. Oncology Reports, 2017, 38, 1760-1766.	1.2	25
251	An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma. Oncotarget, 2017, 8, 71070-71079.	0.8	4
252	Association of Inflammasome Components in Background Liver with Poor Prognosis After Curatively-resected Hepatocellular Carcinoma. Anticancer Research, 2017, 37, 293-300.	0.5	18

#	Article	IF	CITATIONS
253	Quality of life after total <i>vs</i> distal gastrectomy with Roux-en-Y reconstruction: Use of the Postgastrectomy Syndrome Assessment Scale-45. World Journal of Gastroenterology, 2017, 23, 2068.	1.4	39
254	Clinical utility of the platelet-lymphocyte ratio as a predictor of postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer. World Journal of Gastroenterology, 2017, 23, 2519.	1.4	43
255	Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study. World Journal of Gastroenterology, 2017, 23, 1090.	1.4	9
256	Splenic Aneurysm Near the Origin of Splenic Artery and Splenic Hamartoma with Stricture of the Celiac Artery Due to Median Arcuate Ligament Compression. Japanese Journal of Gastroenterological Surgery, 2017, 50, 728-735.	0.0	1
257	Usefulness of Intraoperative Angiography in a Hybrid Operating Room for Pancreaticoduodenectomy in Patients with Celiac Axis Stenosis: Report of Two Cases. Japanese Journal of Gastroenterological Surgery, 2017, 50, 956-964.	0.0	1
258	Retroperitoneal Nerve Plexus Dissection During Pancreatoduodenectomy. , 2017, , 193-200.		0
259	Tumor-Forming Autoimmune Pancreatitis Confused with Pancreatic Cancer That Developed during the Course of Chronic Pancreatitis. Japanese Journal of Gastroenterological Surgery, 2017, 50, 888-896.	0.0	0
260	Molecular mechanisms of peritoneal dissemination in gastric cancer. World Journal of Gastroenterology, 2016, 22, 6829.	1.4	121
261	Transumbilical Single-Port Laparoscopic Surgery for Colorectal Cancers: Experience of 258 Consecutive Cases with Rational Manipulation of Instrument for Safety and Benefit. Annals of Cancer Research and Therapy, 2016, 24, 7-11.	0.1	3
262	Detection of serum melanoma-associated antigen D4 in patients with squamous cell carcinoma of the esophagus. Ecological Management and Restoration, 2016, 29, 663-669.	0.2	3
263	S-1 plus <i>nab</i> -paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. Journal of Surgical Oncology, 2016, 113, 413-419.	0.8	14
264	Salvage pharyngolaryngectomy with total esophagectomy following definitive chemoradiotherapy. Ecological Management and Restoration, 2016, 29, 598-602.	0.2	14
265	Modified twoâ€dimensional response as surrogate marker of overall survival in patients with metastatic colorectal cancer. Cancer Science, 2016, 107, 1492-1498.	1.7	5
266	Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer. Oncology Reports, 2016, 35, 1727-1731.	1.2	71
267	Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer. Medicine (United States), 2016, 95, e3781.	0.4	105
268	Prognostic relevance of SAMSN1 expression in gastric cancer. Oncology Letters, 2016, 12, 4708-4716.	0.8	16
269	Preoperative Identification of a Prognostic Factor for Pancreatic Neuroendocrine Tumors Using Multiphase Contrast-Enhanced Computed Tomography. Pancreas, 2016, 45, 198-203.	0.5	27
270	NRAGE promotes the malignant phenotype of hepatocellular carcinoma. Oncology Letters, 2016, 11, 1847-1854.	0.8	26

#	Article	IF	CITATIONS
271	Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer. Langenbeck's Archives of Surgery, 2016, 401, 1143-1152.	0.8	28
272	Adverse impact of low skeletal muscle index on the prognosis of hepatocellular carcinoma after hepatic resection. International Journal of Surgery, 2016, 30, 136-142.	1.1	54
273	Neurotrophin Receptor-Interacting Melanoma Antigen-Encoding Gene Homolog is Associated with Malignant Phenotype of Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 532-539.	0.7	17
274	Quantitative assessment of chemotherapyâ€induced peripheral neurotoxicity using a pointâ€ofâ€care nerve conduction device. Cancer Science, 2016, 107, 1453-1457.	1.7	28
275	Bone Scan Index predicts skeletal-related events in patients with metastatic breast cancer. SpringerPlus, 2016, 5, 1095.	1.2	11
276	Role for Daple in non anonical Wnt signaling during gastric cancer invasion and metastasis. Cancer Science, 2016, 107, 133-139.	1.7	40
277	Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer. International Journal of Cancer, 2016, 139, 2290-2298.	2.3	39
278	The current state of stomach cancer surgery in the world. Japanese Journal of Clinical Oncology, 2016, 46, 1062-1071.	0.6	13
279	Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer. International Journal of Oncology, 2016, 49, 1195-1202.	1.4	40
280	Incidence and risk factors for anastomotic stenosis of continuous hepaticojejunostomy after pancreaticoduodenectomy. Journal of Hepato-Biliary-Pancreatic Sciences, 2016, 23, 628-635.	1.4	34
281	Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer. Medicine (United) Tj ETQq1 1	0.784314 0.4	rgBT /Overloo
282	Changes in exercise capacity, muscle strength, and health-related quality of life in esophageal cancer patients undergoing esophagectomy. BMC Sports Science, Medicine and Rehabilitation, 2016, 8, 34.	0.7	26
283	The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity. Medicine (United States), 2016, 95, e4282.	0.4	28
284	Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue. Oncology Letters, 2016, 12, 4821-4828.	0.8	17
285	Predictive value of drain amylase content for peripancreatic inflammatory fluid collections after laparoscopic (assisted) distal gastrectomy. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 4353-4362.	1.3	20
286	Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. BMC Cancer, 2016, 16, 248.	1.1	78
287	A resected case of symptomatic acinar cell cystadenoma of the pancreas displacing the main pancreatic duct. Surgical Case Reports, 2016, 2, 39.	0.2	12
288	Function and diagnostic value of <scp>Anosminâ€l </scp> in gastric cancer progression. International Journal of Cancer, 2016, 138, 721-730.	2.3	55

#	Article	IF	CITATIONS
289	Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer, 2016, 19, 255-263.	2.7	70
290	Assessment of postoperative quality of life following pylorus-preserving gastrectomy and Billroth-I distal gastrectomy in gastric cancer patients: results of the nationwide postgastrectomy syndrome assessment study. Gastric Cancer, 2016, 19, 302-311.	2.7	62
291	Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer, 2016, 19, 329-338.	2.7	242
292	Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701). International Journal of Clinical Oncology, 2016, 21, 557-565.	1.0	11
293	Evaluation of the efficacy of daikenchuto (TJ -100) for the prevention of paralytic ileus after pancreaticoduodenectomy: A multicenter, double-blind, randomized, placebo-controlled trial. Surgery, 2016, 159, 1333-1341.	1.0	23
294	Tumor Infiltrative Pattern Predicts Sites of Recurrence After Curative Gastrectomy for Stages 2 and 3 Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 1934-1940.	0.7	38
295	Adverse Effects of Intraoperative Blood Loss on Long-Term Outcomes after Curative Gastrectomy of Patients with Stage II/III Gastric Cancer. Digestive Surgery, 2016, 33, 121-128.	0.6	43
296	Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). Gastric Cancer, 2016, 19, 839-851.	2.7	51
297	Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. Gastric Cancer, 2016, 19, 15-20.	2.7	51
298	Modified Blumgart Suturing Technique for Remnant Closure After Distal Pancreatectomy: a Propensity Score-Matched Analysis. Journal of Gastrointestinal Surgery, 2016, 20, 374-384.	0.9	17
299	Exploratory phase II trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial). Gastric Cancer, 2016, 19, 350-360.	2.7	14
300	Comparison of the international consensus guidelines for predicting malignancy in intraductal papillary mucinous neoplasms. Surgery, 2016, 159, 878-884.	1.0	53
301	The Prognostic Relevance of Subcarinal Lymph Node Dissection in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2016, 23, 611-618.	0.7	19
302	Quality of life and nutritional consequences after aboral pouch reconstruction following total gastrectomy for gastric cancer: randomized controlled trial CCG1101. Gastric Cancer, 2016, 19, 977-985.	2.7	26
303	Extremity in surgeon volume: Korea may be the place to go if you want to be a decent gastric surgeon. Gastric Cancer, 2016, 19, 323-325.	2.7	6
304	Combination of continuous paravertebral block and epidural anesthesia in postoperative pain control after esophagectomy. Esophagus, 2016, 13, 42-47.	1.0	10
305	The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression. Annals of Surgical Oncology, 2016, 23, 214-221.	0.7	41
306	Phase III study of intraperitoneal paclitaxel plus s-1/paclitaxel compared with s-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial Journal of Clinical Oncology, 2016, 34, 4014-4014.	0.8	11

#	Article	IF	CITATIONS
307	Metastatic pathway-specific transcriptome analysis identifies <i>MFSD4</i> as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Oncotarget, 2016, 7, 13667-13679.	0.8	46
308	Correlation Between Poor Prognosis and Lower TPPP Gene Expression in Hepatocellular Carcinoma. Anticancer Research, 2016, 36, 4639-4646.	0.5	7
309	Factors affecting the quality of life of patients after gastrectomy as assessed using the newly developed PGSAS-45 scale: A nationwide multi-institutional study. World Journal of Gastroenterology, 2016, 22, 8978.	1.4	34
310	Systemic hemodynamics in advanced cirrhosis: Concerns during perioperative period of liver transplantation. World Journal of Hepatology, 2016, 8, 1047.	0.8	19
311	Autoimmune Pancreatitis Mimicking Remnant Pancreatic Recurrence after Curative Resection of Pancreatic Body Cancer. Japanese Journal of Gastroenterological Surgery, 2016, 49, 524-532.	0.0	1
312	Short-term outcomes after conventional transthoracic esophagectomy. Nagoya Journal of Medical Science, 2016, 78, 69-78.	0.6	10
313	Clinical significance of zinc-finger E-box binding homeobox 1 mRNA levels in peritoneal washing for gastric cancer. Molecular and Clinical Oncology, 2015, 3, 435-441.	0.4	12
314	Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft. International Journal of Cancer, 2015, 136, 1718-1730.	2.3	49
315	Multicenter comparative study of laparoscopic and open distal pancreatectomy using propensity scoreâ€matching. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 731-736.	1.4	95
316	Cancer therapy using non-thermal atmospheric pressure plasma with ultra-high electron density. Physics of Plasmas, 2015, 22, .	0.7	56
317	Excess Weight Adversely Influences Treatment Length of Postoperative Pancreatic Fistula. Pancreas, 2015, 44, 971-976.	0.5	24
318	Postoperative elevation of CA15-3 due to pernicious anemia in a patient without evidence of breast cancer recurrence. Surgical Case Reports, 2015, 1, 126.	0.2	6
319	<i>CD44</i> single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence. Journal of Surgical Oncology, 2015, 112, 622-628.	0.8	14
320	SMAD4 Expression Predicts Local Spread and Treatment Failure in Resected Pancreatic Cancer. Pancreas, 2015, 44, 660-664.	0.5	57
321	A Vascular Endothelial Growth Factor Gene Polymorphism Predicts Malignant Potential in Intraductal Papillary Mucinous Neoplasm. Pancreas, 2015, 44, 608-614.	0.5	2
322	Factors related to occurrence and aggravation of pancreatic fistula after radical gastrectomy for gastric cancer. Journal of Surgical Oncology, 2015, 112, 381-386.	0.8	23
323	Oral Food Intake Versus Fasting on Postoperative Pancreatic Fistula After Distal Pancreatectomy. Medicine (United States), 2015, 94, e2398.	0.4	15
324	Recent advances in the molecular diagnostics of gastric cancer. World Journal of Gastroenterology, 2015, 21, 9838.	1.4	92

#	Article	IF	CITATIONS
325	Expression of membrane complement regulators, CD46, CD55 and CD59, in mesothelial cells of patients on peritoneal dialysis therapy. Molecular Immunology, 2015, 65, 302-309.	1.0	16
326	Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment. Medicine (United States), 2015, 94, e1647.	0.4	55
327	Effectiveness of plasma treatment on pancreatic cancer cells. International Journal of Oncology, 2015, 47, 1655-1662.	1.4	98
328	Translational implication of Kallmann syndrome-1 gene expression in hepatocellular carcinoma. International Journal of Oncology, 2015, 46, 2546-2554.	1.4	11
329	Adherens junctions associated protein 1 serves as a predictor of recurrence of squamous cell carcinoma of the esophagus. International Journal of Oncology, 2015, 47, 1811-1818.	1.4	24
330	Significance of the Splenic Vein and Its Branches in Pancreatoduodenectomy with Resection of the Portal Vein System. Digestive Surgery, 2015, 32, 382-388.	0.6	26
331	B-cell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma. International Journal of Oncology, 2015, 46, 641-648.	1.4	39
332	CCNJ detected by triple combination array analysis as a tumor-related gene of hepatocellular carcinoma. International Journal of Oncology, 2015, 46, 1963-1970.	1.4	14
333	High expression of Janus kinase 2 in background normal liver tissue of resected hepatocellular carcinoma is associated with worse prognosis. Oncology Reports, 2015, 33, 767-773.	1.2	8
334	Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. Journal of Gastroenterology, 2015, 50, 590-600.	2.3	31
335	Method of Bilateral Pleural Drainage by Single Blake Drain After Esophagectomy. World Journal of Surgery, 2015, 39, 727-731.	0.8	5
336	Diversity of Clinical Implication of B-Cell Translocation Gene 1 Expression by Histopathologic and Anatomic Subtypes of Gastric Cancer. Digestive Diseases and Sciences, 2015, 60, 1256-1264.	1.1	40
337	Protein tyrosine kinase 7: a hepatocellular carcinoma-related gene detected by triple-combination array. Journal of Surgical Research, 2015, 195, 444-453.	0.8	10
338	Reduced Expression of Adherens Junctions Associated Protein 1 Predicts Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. Annals of Surgical Oncology, 2015, 22, 1499-1507.	0.7	25
339	Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy. Oncology Letters, 2015, 9, 1201-1206.	0.8	18
340	Vein resections >3Âcm during pancreatectomy are associated withÂpoor 1-year patency rates. Surgery, 2015, 157, 708-715.	1.0	51
341	Optimal Roux-en-Y reconstruction after distal gastrectomy for early gastric cancer as assessed using the newly developed PGSAS-45 scale. Surgery Today, 2015, 45, 1307-1316.	0.7	5
342	Influence of Food Intake on the Healing Process of Postoperative Pancreatic Fistula After Pancreatoduodenectomy: A Multi-institutional Randomized Controlled Trial. Annals of Surgical Oncology, 2015, 22, 3905-3912.	0.7	34

#	Article	IF	CITATIONS
343	Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2015, 22, 1453-1460.	0.7	17
344	Serosal Invasion Strongly Associated With Recurrence After Curative Hepatic Resection of Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e602.	0.4	11
345	Preoperative Internal Biliary Drainage Increases the Risk of Bile Juice Infection and Pancreatic Fistula After Pancreatoduodenectomy. Pancreas, 2015, 44, 465-470.	0.5	58
346	Feeding Duodenostomy Decreases the Incidence of Mechanical Obstruction After Radical Esophageal Cancer Surgery. World Journal of Surgery, 2015, 39, 1105-1110.	0.8	22
347	Updated evidence on adjuvant treatments for gastric cancer. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1549-1560.	1.4	47
348	Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis. Surgery, 2015, 158, 1573-1580.	1.0	53
349	Overexpression of melanoma-associated antigen D4 is an independent prognostic factor in squamous cell carcinoma of the esophagus. Ecological Management and Restoration, 2015, 28, 188-195.	0.2	15
350	Plasma with high electron density and plasma-activated medium for cancer treatment. Clinical Plasma Medicine, 2015, 3, 72-76.	3.2	55
351	Gastric adenocarcinoma with para-aortic lymph node metastasis: a borderline resectable cancer?. Surgery Today, 2015, 45, 1082-1090.	0.7	25
352	Effectiveness of plasma treatment on gastric cancer cells. Gastric Cancer, 2015, 18, 635-643.	2.7	83
353	Characteristics and clinical relevance of postgastrectomy syndrome assessment scale (PGSAS)-45: newly developed integrated questionnaires for assessment of living status and quality of life in postgastrectomy patients. Gastric Cancer, 2015, 18, 147-158.	2.7	113
354	Factors that minimize postgastrectomy symptoms following pylorus-preserving gastrectomy: assessment using a newly developed scale (PGSAS-45). Gastric Cancer, 2015, 18, 397-406.	2.7	29
355	Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer. Gastric Cancer, 2015, 18, 288-296.	2.7	45
356	Long-term quality of life after laparoscopic distal gastrectomy for early gastric cancer: results of a prospective multi-institutional comparative trial. Gastric Cancer, 2015, 18, 417-425.	2.7	43
357	Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by Postgastrectomy Syndrome Assessment Scale (PGSAS-45): a nationwide multi-institutional study. Gastric Cancer, 2015, 18, 407-416.	2.7	166
358	More than 6 months of postoperative adjuvant chemotherapy results in loss of skeletal muscle: a challenge to the current standard of care. Gastric Cancer, 2015, 18, 203-204.	2.7	16
359	A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106). Gastric Cancer, 2015, 18, 354-359.	2.7	10
360	A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer who relapsed after S-1 adjuvant therapy, XP after TS-1 adjuvant failure (XParTS) Journal of Clinical Oncology, 2015, 33, 124-124.	0.8	1

#	Article	IF	CITATIONS
361	Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 10584.	1.4	66
362	Intraductal Papillary Mucinous Carcinoma with Portal Annular Pancreas Anomaly Treated by Middle-preserving Pancreatectomy. Japanese Journal of Gastroenterological Surgery, 2015, 48, 706-714.	0.0	2
363	Estimated pancreatic parenchymal remnant volume accurately predicts clinically relevant pancreatic fistula after pancreatoduodenectomy. Surgery, 2014, 156, 601-610.	1.0	38
364	Decreased expression of prenyl diphosphate synthase subunit 2 correlates with reduced survival of patients with gastric cancer. Journal of Experimental and Clinical Cancer Research, 2014, 33, 88.	3.5	27
365	Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus. Oncology Reports, 2014, 31, 693-700.	1.2	24
366	Epithelialâ€ŧoâ€mesenchymal transition predicts prognosis in clinical gastric cancer. Journal of Surgical Oncology, 2014, 109, 684-689.	0.8	60
367	Clinical significance of expression and epigenetic profiling of <i>TUSC1</i> in gastric cancer. Journal of Surgical Oncology, 2014, 110, 136-144.	0.8	30
368	Development and external validation of a nomogram for overall survival after curative resection in serosa-negative, locally advanced gastric cancer. Annals of Oncology, 2014, 25, 1179-1184.	0.6	99
369	Comparison of inflammationâ€based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 682-688.	1.4	72
370	Identification of the collagen type 1 alpha 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma. BMC Cancer, 2014, 14, 108.	1.1	71
371	A Randomized Phase III Trial Exploring the Prognostic Value of Extensive Intraoperative Peritoneal Lavage in Addition to Standard Treatment for Resectable Advanced Gastric Cancer: CCOG 1102 Study. Japanese Journal of Clinical Oncology, 2014, 44, 101-103.	0.6	21
372	The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 847-855.	1.1	45
373	Clinical Implication of Morphological Subtypes in Management of Intraductal Papillary Mucinous Neoplasm. Annals of Surgical Oncology, 2014, 21, 2444-2452.	0.7	41
374	Overexpression of L1CAM is Associated with Tumor Progression and Prognosis via ERK Signaling in Gastric Cancer. Annals of Surgical Oncology, 2014, 21, 560-568.	0.7	22
375	Combination Treatment of Human Pancreatic Cancer Xenograft Models with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib and Oncolytic Herpes Simplex Virus HF10. Annals of Surgical Oncology, 2014, 21, 691-698.	0.7	23
376	Preservation of the Pyloric Ring Confers Little Benefit in Patients Undergoing Total Pancreatectomy. World Journal of Surgery, 2014, 38, 1807-1813.	0.8	8
377	Surgeons strive hard to break the Da Vinci code. Gastric Cancer, 2014, 17, 399-401.	2.7	0
378	Modified Blumgart Anastomosis for Pancreaticojejunostomy: Technical Improvement in Matched Historical Control Study. Journal of Gastrointestinal Surgery, 2014, 18, 1108-1115.	0.9	145

#	Article	IF	CITATIONS
379	Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer, 2014, 17, 206-212.	2.7	100
380	Epithelial to mesenchymal transition correlates with tumor budding and predicts prognosis in esophageal squamous cell carcinoma. Journal of Surgical Oncology, 2014, 110, 764-769.	0.8	51
381	Epithelial to mesenchymal transition might be induced via CD44 isoform switching in colorectal cancer. Journal of Surgical Oncology, 2014, 110, 745-751.	0.8	42
382	Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer. Journal of Experimental and Clinical Cancer Research, 2014, 33, 66.	3.5	49
383	The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surgery Today, 2014, 44, 1692-1701.	0.7	41
384	Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines. Gastric Cancer, 2014, 17, 450-462.	2.7	20
385	Expression Analysis of THOP1 in Background Liver, a Prognostic Predictive Factor in Hepatocellular Carcinoma, Extracted by Multiarray Analysis. Annals of Surgical Oncology, 2014, 21, 443-450.	0.7	20
386	Epithelial to Mesenchymal Transition is Associated with Shorter Disease-Free Survival in Hepatocellular Carcinoma. Annals of Surgical Oncology, 2014, 21, 3882-3890.	0.7	61
387	Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma. Oncology Reports, 2014, 31, 1305-1313.	1.2	19
388	Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. International Journal of Oncology, 2014, 44, 44-52.	1.4	41
389	Hepatectomy for hepatocellular carcinoma in patients with hemophilia. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 824-828.	1.4	12
390	Pancreatoduodenectomy With Portal Vein Resection Is Feasible and Potentially Beneficial for Elderly Patients With Pancreatic Cancer. Pancreas, 2014, 43, 951-958.	0.5	25
391	Clinical utility of PDSS2 expression to stratify patients at risk for recurrence of hepatocellular carcinoma. International Journal of Oncology, 2014, 45, 2005-2012.	1.4	17
392	Novel diagnostics for aggravating pancreatic fistulas at the acute phase after pancreatectomy. World Journal of Gastroenterology, 2014, 20, 8535.	1.4	41
393	Follow-up after gastrectomy for cancer: Results of an international web round table. World Journal of Gastroenterology, 2014, 20, 11966.	1.4	19
394	A Case of Carcinoma of the Ampulla of Vater with Anomaly of the Portal Venous System: Prepancreatic Postduodenal Portal Vein. Japanese Journal of Gastroenterological Surgery, 2014, 47, 275-280.	0.0	5
395	Effect of landiolol hydrochloride on tachyarrhythmia after esophagectomy. Hepato-Gastroenterology, 2014, 61, 1546-51.	0.5	4
396	Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. Hepato-Gastroenterology, 2014, 61, 1756-61.	0.5	24

#	Article	IF	CITATIONS
397	Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer. Hepato-Gastroenterology, 2014, 61, 599-605.	0.5	23
398	CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702). Cancer Chemotherapy and Pharmacology, 2013, 72, 629-635.	1.1	9
399	Tumor budding as a useful prognostic marker in T1â€stage squamous cell carcinoma of the esophagus. Journal of Surgical Oncology, 2013, 108, 42-46.	0.8	43
400	Mo1767 Development and Validation of Pgsas-45, an Integrated Questionnaire to Assess Postgastrectomy Syndrome. Gastroenterology, 2013, 144, S-1111.	0.6	4
401	Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Surgery, 2013, 154, 946-954.	1.0	113
402	Reduced port surgery for gastric cancer: another giant leap for mankind?. Gastric Cancer, 2013, 16, 457-459.	2.7	10
403	Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. Journal of Experimental and Clinical Cancer Research, 2013, 32, 65.	3.5	16
404	Evaluation of MAGEâ€D4 expression in hepatocellular carcinoma in Japanese patients. Journal of Surgical Oncology, 2013, 108, 557-562.	0.8	22
405	Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer, 2013, 16, 1-27.	2.7	396
406	Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells. Cancer Letters, 2013, 331, 220-229.	3.2	19
407	Introduction of laparoscopy-assisted distal gastrectomy: a tale of two cities. Gastric Cancer, 2013, 16, 115-117.	2.7	2
408	Effect of Daikenchuto (TJ-100) on Postoperative Bowel Motility and on Prevention of Paralytic Ileus after Pancreaticoduodenectomy: A Multicenter, Randomized, Placebo-controlled Phase II Trial (The) Tj ETQq0 0 C) rg®.76/Ov€	erlaøk 10 Tf 5
409	Aggressive Surgery for Borderline Resectable Pancreatic Cancer. Pancreas, 2013, 42, 1004-1010.	0.5	87
410	Surgery for Gastric Cancer: Has the East versus West Issue Been Solved?. Digestive Surgery, 2013, 30, 92-95.	0.6	6
411	Blue–Green Emission in Terbiumâ€Đoped Alumina (Tb:Al ₂ O ₃) Transparent Ceramics. Advanced Functional Materials, 2013, 23, 6036-6043.	7.8	82
412	Estrogen receptor 1 gene as a tumor suppressor gene in hepatocellular carcinoma detected by triple-combination array analysis. International Journal of Oncology, 2013, 43, 88-94.	1.4	81
413	A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. OncoTargets and Therapy, 2013, 6, 1805.	1.0	18
414	Dynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis. OncoTargets and Therapy, 2013, 6, 1417.	1.0	32

#	Article	IF	CITATIONS
415	Gastric cancer with minimal peritoneal metastasis: is this a sign to give up or to treat more aggressively?. Nagoya Journal of Medical Science, 2013, 75, 3-10.	0.6	11
416	Correlation Between Radiographic Classification and Pathological Grade of Portal Vein Wall Invasion in Pancreatic Head Cancer. Annals of Surgery, 2012, 255, 103-108.	2.1	166
417	A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). BMC Cancer, 2012, 12, 307.	1.1	12
418	Preservation of the Pyloric Ring Has Little Value in Surgery for Pancreatic Head Cancer: A Comparative Study Comparing Three Surgical Procedures. Annals of Surgical Oncology, 2012, 19, 176-183.	0.7	58
419	The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801). Cancer Chemotherapy and Pharmacology, 2012, 70, 575-581.	1.1	11
420	Clinicopathologic Study of Intrapancreatic Cancer Spread in Carcinoma of the Body and Tail of the Pancreas. Pancreas, 2012, 41, 753-758.	0.5	5
421	Single-institute prospective trial of laparoscopy-assisted distal gastrectomy with systemic lymph node dissection for early gastric carcinoma. Gastric Cancer, 2012, 15, 124-130.	2.7	15
422	Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer, 2012, 15, 335-337.	2.7	68
423	Suppressor of Cytokine Signaling 4 Detected as a Novel Gastric Cancer Suppressor Gene using Double Combination Array Analysis. World Journal of Surgery, 2012, 36, 362-372.	0.8	27
424	Combination of the Tumor Angiogenesis Inhibitor Bevacizumab and Intratumoral Oncolytic Herpes Virus Injections as a Treatment Strategy for Human Gastric Cancers. Hepato-Gastroenterology, 2012, 59, 1844-50.	0.5	10
425	Incidence and Management of Anastomotic Leakage. , 2012, , 127-132.		0
426	Identification of the bleomycin hydrolase gene as a methylated tumor suppressor gene in hepatocellular carcinoma using a novel triple-combination array method. Cancer Letters, 2011, 312, 150-157.	3.2	23
427	Pattern of Lymph Node Metastasis Spread in Pancreatic Cancer. Pancreas, 2011, 40, 951-955.	0.5	89
428	Comparison of Pancreatic Head Resection With Segmental Duodenectomy and Pylorus-Preserving Pancreatoduodenectomy for Benign and Low-Grade Malignant Neoplasms of the Pancreatic Head. Pancreas, 2011, 40, 1258-1263.	0.5	28
429	Prognostic Implications of Lymph Node Metastases in Carcinoma of the Body and Tail of the Pancreas. Pancreas, 2011, 40, 1029-1033.	0.5	35
430	Impact of Operative Blood Loss on Survival in Invasive Ductal Adenocarcinoma of the Pancreas. Pancreas, 2011, 40, 3-9.	0.5	63
431	Recurrence Pattern and Prognosis of Pancreatic Cancer After Pancreatic Fistula. Annals of Surgical Oncology, 2011, 18, 2329-2337.	0.7	56
432	Construct validity of the LapVR virtual-reality surgical simulator. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 423-428.	1.3	54

#	Article	IF	CITATIONS
433	Nutritional recovery after open and laparoscopic gastrectomies. Gastric Cancer, 2011, 14, 144-149.	2.7	57
434	Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer, 2011, 14, 301-316.	2.7	253
435	Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study. International Journal of Clinical Oncology, 2011, 16, 506-511.	1.0	15
436	Assessment of Quality of Life After Gastrectomy Using EORTC QLQ 30 and STO22. World Journal of Surgery, 2011, 35, 357-364.	0.8	113
437	A Randomized Phase II Trial to Test the Efficacy of Intra-peritoneal Paclitaxel for Gastric Cancer with High Risk for the Peritoneal Metastasis (INPACT Trial). Japanese Journal of Clinical Oncology, 2011, 41, 283-286.	0.6	18
438	Impact of clinical response to first-line chemotherapy on gastric cancer patients treated with second-line and third-line chemotherapy. Hepato-Gastroenterology, 2011, 58, 1041-5.	0.5	2
439	Invasion of the Splenic Artery Is a Crucial Prognostic Factor in Carcinoma of the Body and Tail of the Pancreas. Annals of Surgery, 2010, 251, 483-487.	2.1	65
440	Amylase Concentration of the Drainage Fluid as a Risk Factor for Intraâ€abdominal Abscess Following Gastrectomy for Gastric Cancer. World Journal of Surgery, 2010, 34, 1534-1539.	0.8	42
441	Phase II Clinical Trial of Postoperative Sâ€IÂMonotherapy for Gastric Cancer Patients with Free Intraperitoneal Cancer Cells Detected by Realâ€Time RTâ€PCR. World Journal of Surgery, 2010, 34, 2083-2089.	0.8	7
442	A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer, 2010, 13, 197-203.	2.7	39
443	Middle pancreatectomy: Safety and long-term results. Surgery, 2010, 147, 21-29.	1.0	82
444	Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. Surgery, 2010, 148, 285-290.	1.0	71
445	Laparoscopic Surgery for Gastric Cancer: A Collective Review with Meta-Analysis of Randomized Trials. Journal of the American College of Surgeons, 2010, 211, 677-686.	0.2	116
446	Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of antiâ€metastatic efficacy between oral Sâ€1 and UFT/ LV. Cancer Science, 2010, 101, 1853-1860.	1.7	10
447	Para-aortic lymph node dissection revisited: Have we been neglecting a promising treatment option for gastric carcinoma?. European Journal of Surgical Oncology, 2010, 36, 447-448.	0.5	7
448	Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer, 2009, 12, 69-78.	2.7	94
449	Radical Surgery for Gastric Carcinoma: It is Not an Issue of Whether to Perform D1 or D2. Dissect as Many Lymph Nodes as Possible and You Will Be Rewarded. Acta Chirurgica Belgica, 2009, 109, 27-35.	0.2	8
450	Pancreatic Cancer With Paraaortic Lymph Node Metastasis. Pancreas, 2009, 38, e13-e17.	0.5	63

#	Article	IF	CITATIONS
451	Turbostratic boron nitride consolidated by SPS. Journal of the Ceramic Society of Japan, 2009, 117, 189-193.	0.5	10
452	Pancreatic cancer with distant metastases: a contraindication for radical surgery?. Hepato-Gastroenterology, 2009, 56, 881-5.	0.5	14
453	Expression of L1 cell adhesion molecule is a significant prognostic factor in pT3-stage gastric cancer. Anticancer Research, 2009, 29, 4033-9.	0.5	12
454	Effect of pulsed DC current on atomic diffusion of Nb–C diffusion couple. Journal of Materials Science, 2008, 43, 6400-6405.	1.7	46
455	Consolidation of SiC/BN composite through MA-SPS method. Journal of Materials Science, 2008, 43, 6422-6428.	1.7	18
456	The Number of Metastatic Lymph Nodes is a Significant Risk Factor for Bone Metastasis and Poor Outcome After Surgery for Linitis Plasticaâ€ŧype Gastric Carcinoma. World Journal of Surgery, 2008, 32, 2015-2020.	0.8	21
457	Disseminated cancer cells in the peritoneal cavity: what can we do when we detect them?. Gastric Cancer, 2008, 11, 192-193.	2.7	4
458	Multivariate Analysis of the Pathologic Features of Esophageal Squamous Cell Cancer: Tumor Budding Is a Significant Independent Prognostic Factor. Annals of Surgical Oncology, 2008, 15, 1977-1982.	0.7	94
459	Longterm Outcomes of Early-Stage Gastric Carcinoma Patients Treated with Laparoscopy-Assisted Surgery. Journal of the American College of Surgeons, 2008, 206, 138-143.	0.2	81
460	Influence of pulsed DC current and electric field on growth of carbide ceramics during spark plasma sintering. Journal of the Ceramic Society of Japan, 2008, 116, 1187-1192.	0.5	25
461	Enhanced Growth of Mo2C formed in Mo-C Diffusion Couple by Pulsed DC Current. Funtai Oyobi Fummatsu Yakin/Journal of the Japan Society of Powder and Powder Metallurgy, 2008, 55, 643-650.	0.1	12
462	Clinical Implications of Peritoneal Cytology in Potentially Resectable Pancreatic Cancer. Annals of Surgery, 2007, 246, 254-258.	2.1	56
463	Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: Correlation with drug sensitivity against 5-fluorouracil. Cancer Letters, 2007, 252, 307-313.	3.2	29
464	Detection of Minimal Gastric Cancer Cells in Peritoneal Washings by Focused Microarray Analysis with Multiple Markers: Clinical Implications. Annals of Surgical Oncology, 2007, 14, 1694-1702.	0.7	29
465	The beginning of a new era: East meets West more comfortably regarding lymphadenectomy for gastric cancer — Japan will finally drop the surgery-alone arm in its pursuit of a multimodal treatment strategy. Gastric Cancer, 2007, 10, 69-74.	2.7	8
466	Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. Hepato-Gastroenterology, 2007, 54, 960-3.	0.5	23
467	A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study). Anticancer Research, 2007, 27, 2667-71.	0.5	78
468	P16 methylation in serum as a potential marker for the malignancy of colorectal carcinoma. Anticancer Research, 2007, 27, 3367-70.	0.5	21

#	Article	IF	CITATIONS
469	Effect of sintering condition on thermal and electrical properties of dense β-SiC fabricated by MA-SPS method. Physica Status Solidi C: Current Topics in Solid State Physics, 2006, 3, 2876-2879.	0.8	5
470	Laparoscopic Wedge Resection for Gastrointestinal Stromal Tumors of the Stomach: Initial Experience. Surgery Today, 2006, 36, 341-347.	0.7	72
471	Role of disorder-order transformation in consolidation of ceramics. Journal of Materials Science, 2006, 41, 727-732.	1.7	17
472	Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer, 2006, 9, 51-66.	2.7	234
473	Disseminated cancer cells in the bone marrow: are they really there at all?. Gastric Cancer, 2006, 9, 243-244.	2.7	1
474	In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues. International Journal of Clinical Oncology, 2006, 11, 449-453.	1.0	18
475	Prognostic Significance of Intraperitoneal Cancer Cells in Gastric Carcinoma: Analysis of Real Time Reverse Transcriptase-Polymerase Chain Reaction after 5 Years of Followup. Journal of the American College of Surgeons, 2006, 202, 231-236.	0.2	41
476	Biological Significance of Isolated Tumor Cells and Micrometastasis in Lymph Nodes Evaluated Using a Green Fluorescent Protein–Tagged Human Gastric Cancer Cell Line. Clinical Cancer Research, 2006, 12, 361-368.	3.2	37
477	Chemotherapy as a component of multimodal therapy for gastric carcinoma. World Journal of Gastroenterology, 2006, 12, 2000.	1.4	15
478	Influence of Synthesis Temperature on the Defect Structure of Boron Carbide: Experimental and Modeling Studies. Journal of the American Ceramic Society, 2005, 88, 1382-1387.	1.9	79
479	Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. British Journal of Surgery, 2005, 92, 1103-1109.	0.1	171
480	Laparoscopy-assisted distal gastrectomy with systemic lymph node dissection: A phase II study following the learning curve. Journal of Surgical Oncology, 2005, 91, 26-32.	0.8	52
481	Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: detection of cytokeratin 20 mRNA in peritoneal washes, in addition to detection of carcinoembryonic antigen. Gastric Cancer, 2005, 8, 142-148.	2.7	48
482	Establishment and characterization of three novel human gastric cancer cell lines with differentiated intestinal phenotype derived from liver metastasis. Clinical and Experimental Metastasis, 2005, 22, 137-147.	1.7	19
483	A Randomized Phase III trial of Post-operative Adjuvant Oral Fluoropyrimidine versus Sequential Paclitaxel/Oral Fluoropyrimidine; and UFT versus S1 for T3/T4 Gastric Carcinoma: The Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial. Japanese Journal of Clinical Oncology, 2005, 35, 672-675.	0.6	35
484	Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice. International Journal of Oncology, 2005, 27, 637-44.	1.4	15
485	Combination of oral fluoropyrimidine and docetaxel: reappraisal of synergistic effect against gastric carcinoma xenografts. In Vivo, 2005, 19, 861-6.	0.6	12
486	Current Surgical Management of Gastric Carcinoma: Global Standards and Japanese Modifications. Cancer Reviews: Asia-Pacific, 2004, 02, 39-50.	0.1	1

#	Article	IF	CITATIONS
487	Detection of Disseminated Cancer Cells in Linitis Plastica-type Gastric Carcinoma. Japanese Journal of Clinical Oncology, 2004, 34, 525-531.	0.6	28
488	Synthesis of (Mg,Si)Al2O4Spinel from Aluminum Dross. Journal of the American Ceramic Society, 2004, 87, 496-499.	1.9	29
489	Consolidation of Nanostructured β‣iC by Spark Plasma Sintering. Journal of the American Ceramic Society, 2004, 87, 1436-1441.	1.9	107
490	Consolidation of nanostructured SiC with disorder–order transformation. Scripta Materialia, 2004, 50, 111-114.	2.6	93
491	Laparoscopy-assisted distal gastrectomy with systemic lymph node dissection: A critical reappraisal from the viewpoint of lymph node retrieval1 1No competing interests declared Journal of the American College of Surgeons, 2004, 198, 933-938.	0.2	88
492	Treatment and Risk Factors for Recurrence after Curative Resection of Gastrointestinal Stromal Tumors of the Stomach. World Journal of Surgery, 2004, 28, 870-875.	0.8	40
493	Adjuvant chemotherapy for gastric cancer in Japan: global and Japanese perspectives. Cancer Chemotherapy and Pharmacology, 2004, 54 Suppl 1, S25-31.	1.1	15
494	Obesity and outcome of distal gastrectomy with D2 lymphadenectomy for carcinoma. Hepato-Gastroenterology, 2004, 51, 1225-8.	0.5	38
495	Laparoscopy-assisted distal gastrectomy with systemic lymph node dissection for early gastric carcinoma: a review of 43 cases. Journal of the American College of Surgeons, 2003, 196, 75-81.	0.2	97
496	Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Cancer Science, 2003, 94, 112-118.	1.7	40
497	Follow-Up Surveillance for Recurrence After Curative Gastric Cancer Surgery Lacks Survival Benefit. Annals of Surgical Oncology, 2003, 10, 898-902.	0.7	89
498	Quantitative Detection of Disseminated Free Cancer Cells in Peritoneal Washes With Real-Time Reverse Transcriptase–Polymerase Chain Reaction. Annals of Surgery, 2002, 235, 499-506.	2.1	112
499	Extended lymph node dissection in gastric carcinoma. Journal of the American College of Surgeons, 2002, 195, 855-864.	0.2	70
500	The role of surgery in the current treatment of gastric carcinoma. Gastric Cancer, 2002, 5, 13-16.	2.7	26
501	Is Borrmann type IV gastric carcinoma a surgical disease? An old problem revisited with reference to the result of peritoneal washing cytology. Journal of Surgical Oncology, 2001, 78, 175-181.	0.8	28
502	Small Incisional Esophagectomy with Endoscopic Assistance: Evaluation of a New Technique. Surgery Today, 2001, 31, 378-382.	0.7	5
503	Rapid quantitative detection of carcinoembryonic antigen-expressing free tumor cells in the peritoneal cavity of gastric-cancer patients with real-time RT-PCR on the lightcycler. International Journal of Cancer, 2000, 89, 411-417.	2.3	97
504	Adenocarcinoma of the gastroesophageal junction in Japan: relevance of Siewert's classification applied to 177 cases resected at a single institution. Journal of the American College of Surgeons, 1999, 189, 594-601.	0.2	81

#	Article	IF	CITATIONS
505	Peritoneal washing cytology: Prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. Journal of Surgical Oncology, 1999, 72, 60-64.	0.8	157
506	Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytology. International Journal of Cancer, 1998, 79, 429-433.	2.3	112
507	A New Macroscopic Classification Predicts Prognosis for Patient With Liver Metastases From Colorectal Cancer. Annals of Surgery, 1997, 226, 582-586.	2.1	72
508	Downregulation of ROBO4 in Pancreatic Cancer Serves as a Biomarker of Poor Prognosis and Indicates Increased Cell Motility and Proliferation Through Activation of MMP-9. Annals of Surgical Oncology, 0, , .	0.7	1